NCT04633239 2026-03-18
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
19 trialsNCT05554328 2026-03-18
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT07371104 2026-03-05
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Daewoong Pharmaceutical Co. LTD.
Phase 1 Recruiting
NCT07024784 2026-03-04
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06712472 2026-01-20
RAINBO-RED
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT06580314 2026-01-14
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT06856499 2026-01-09
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
Phase 1 Recruiting
NCT06545942 2025-12-23
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT04644289 2025-10-03
WoO
AGO Research GmbH
Phase 2 Recruiting
NCT05932862 2025-09-05
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Phase 1 Recruiting
NCT07069335 2025-07-16
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Boryung Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT06686030 2025-04-16
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
Akeso
Phase 2 Recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT06377267 2024-05-09
STROBE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting